Bonalive is a smart biomaterials company transforming the future of healthcare. With one of the most evidence-based technologies in the industry, we are creating a smarter future for healthcare. Bonalive is an ISO 13485:2016 certified, Class III medical device company.
Dr. Ollila founded Bonalive Biomaterials Ltd in 2009, through an MBO of the Bonalive® technology from Vivoxid Ltd. Before he became Chairman and CEO, he completed a post-doc and worked in project management at Novartis Pharma in Switzerland. In addition, Dr. Ollila was also the Global Director of Sales and Marketing at Vivoxid Ltd. He holds a PhD in biochemistry and has an international background, having lived in Finland, Spain, Switzerland and the USA.
Mr. Lucchesi holds a Bachelor of Science in Engineering and joined Bonalive in 2009, after holding several positions as a Research Scientist, Business Development Manager and R&D Manager in different organizations. He has thorough knowledge of the Bonalive technologies and brings his vast experience to the company. Mr. Lucchesi coordinates Bonalive’s scientific projects and oversees their technological development.
Mrs. Rantala joined Bonalive in 2009 after having held several positions in R&D, quality control and project management. A process-oriented thinker, Rantala believes in a lean working philosophy and mentor-based leadership. She holds a degree in laboratory sciences and is a member of the Finnish Production Management Association.
Mrs. Lumiainen joined Bonalive in 2009, after having worked for Vivoxid Ltd since 2002. She has vast experience in marketing and product management, brand design and HR tasks. She holds a Master of Science in Social Sciences and Bachelor of Science in Business Administration.
Ms. Valtanen joined Bonalive in 2011 adding her significant experience in project management, corporate financing and accounting to the company. Ms. Valtanen holds a Master of Science in Economics and Business Administration.
Board of Directors
Dr. Ollila has served as Member of the Board of Directors since 2009 and assumed the role of Chairman of the Board in 2018. He founded Bonalive Biomaterials Ltd in 2009 through a management buy-out of the Bonalive® technology from Vivoxid Ltd. Before his current position as a Chairman and CEO of Bonalive, Dr. Ollila completed a post-doctoral thesis and worked at Novartis Pharma in Switzerland for several years. He was also the Global Director of Sales and Marketing at Vivoxid Ltd. Ollila holds a doctorate in biochemistry from Åbo Akademi University.
Assoc. Prof. Frantzén has been a Member of the Board of Directors since 2013. As a consultant neurosurgeon and Associate Professor at the Turku University Hospital, Frantzén has extensive experience in the clinical use of bioactive glass in spine surgery. Frantzén holds a PhD in Neurosurgery from the University of Turku.
Mr. Muñoz has been a Member of the Board of Directors since 2017. He has extensive international experience from China, India and Colombia. Currently he serves as a New Business Manager (NBO) and Business Development Director at Avalon Pharmaceuticals.
Mr. Rönnlund was appointed to the Board of Directors in 2019. As a marketing and sales executive in the US and Europe, he has extensive experience from Go-To-Market strategies and brand creation. Mr. Rönnlund holds an MSc in Engineering and an MSc in Economics from Åbo Akademi University.
Patient case: Chronic bone infectionJune 26, 2020 08:25
A 13 year old boy was diagnosed with chronic osteomyelitis in the distal tibia. He was operated 8 times and received a large amount of antibiotics and painkillers, but the...
Message from the CEO: Gearing up for a new normalJune 23, 2020 12:49
At Bonalive, we have focused our activities these last few months on targeted projects to redefine our approach to the realities brought about by COVID-19. Our most critical services in...
Video libraryMay 25, 2020 15:01
Get access to the following videos: scientific presentations surgical techniques interviews with surgeons webinars
Brochure libraryMay 15, 2020 13:31
Read our indication-specific brochures, including: – product and technology overview – clinical areas of use – patient cases
Mitteilung des GeschäftsführersMarch 27, 2020 17:11
Während ich dieses Schreiben aufsetze, sind wir weit davon entfernt, Schlussfolgerungen hinsichtlich der globalen Auswirkungen, die das Virus zeitigen wird, zu ziehen. Es wird jedoch mit aller Deutlichkeit klar, dass...
Messaggio dal CEOMarch 27, 2020 16:20
Mentre vi scrivo, è troppo presto per trarre conclusioni di ampia portata sugli effetti globali del virus. Ciò che è chiaro, tuttavia, è che, come è già successo in passato,...
Message du PDGMarch 27, 2020 16:19
En écrivant ces mots, il est bien trop tôt pour tirer des conclusions de grande portée sur les effets globaux du virus. Par contre, ce qui est sûr, c’est que...
Mensaje del CEOMarch 27, 2020 16:09
En el momento en que escribo estas líneas, aún es demasiado pronto para sacar conclusiones de mayor proyección sobre los efectos globales del virus. Sin embargo, lo que sí está...
Mensagem do CEOMarch 27, 2020 16:07
Enquanto escrevo este texto, sei que é muito cedo para tirar conclusões em longo prazo sobre os efeitos globais do vírus. O que é evidente, porém, é que, como já...
Message from the CEOMarch 25, 2020 14:29
Read in Italian (Messaggio dal CEO) Read in French (Message du PDG) Read in Spanish (Mensaje del CEO) Read in Portuguese (Mensagem do CEO) Read in German (Mitteilung des Geschäftsführers)...
Bonalive Gold Sponsor of ESTROT 2020February 17, 2020 12:56
As the Gold Sponsor of the ESTROT 2020 congress, Bonalive will host a medical expert symposium in Maastricht. The speaker line-up includes internationally renowned medical specialists within septic bone surgery:...
Septic non-union whitepaperFebruary 7, 2020 13:48
To give detailed guidance on the treatment of septic non-unions with Bonalive® granules (S53P4), we are now sharing the case catalog as a whitepaper. Fill out your contact details below...
Bonalive at EUROSPINE 2019June 6, 2019 11:30
Broadcast starts here on October 16 12:00 UTC +3h (Helsinki) In case you cannot access the stream, please check the following: – Your internet connection – Your browser (recommended:...
10 years of Smart HealingFebruary 13, 2019 09:10
Patient stories Story 1: The ski girl “We might have to amputate your leg.” This is the message a young woman of 18 received after being seriously injured in a...
Read more about Smart Healing™February 13, 2019 09:09
As the world seeks answers to the growing threat of antibiotic resistance, Smart Healing™ stands for Bonalive’s commitment to our customers. It’s what can be expected from us time and...
Bonalive is now on YouTubeFebruary 12, 2019 11:50
Receive instant updates on new videos by subscribing to our channel. We will share the latest congress presentations, surgical technique videos and much more on a regular basis through our...
Bonalive events 2019 – Meet us hereJanuary 3, 2019 16:25
The Bonalive medical education 2019 flyer provides an overview of the main congresses at which we will display our Smart Healing™ solutions during 2019. Please also take a look at...
Bonalive® against biofilm on cochlear implantsNovember 14, 2018 10:15
The promising results of a new study by B. Höing et al. (2018, ahead of print) show the Smart Healing effect of Bonalive® bioactive glass, enabling cost-effective and sustainable procedures...
World Antibiotic Awareness Week 2018November 14, 2018 10:15
Bonalive participates in the World Health Organization’s World Antibiotic Awareness Week by spreading awareness about why antimicrobial resistance is happening, the risks it poses to our future health, and what...
We are devoted to Smart Healing in septic bone surgeryOctober 26, 2018 16:26
Click here to watch our video.
Bonalive Biomaterials Ltd
Tel. +358 401 77 44 00
Biolinja 12, 20750 Turku, Finland
ISO 13485:2016 certified
Bonalive® granules, Bonalive® putty and Bonalive® putty MIS are CE marked products.